Feature | March 12, 2014

Partnership Investigates Remote Robotic PCI at Rural Hospitals

Corindus CorPath Robotic Navigation Telemedicine Telecardiology Cath Lab

March 12, 2014 — For patients living in rural areas, life-saving procedures such as an angioplasty may only be available at a facility more than 200 miles away. To bridge this distance, Corindus Vascular Robotics is partnering with Sanford Health and The Leona M. and Harry B. Helmsley Charitable Trust to launch a feasibility study for a remote robotic systems cath lab telecardiology program. 

Following the feasibility study, the remote robotics program is intended to potentially empower an interventional cardiologist at a major center to robotically control the movement of interventional devices at a remote facility. This could offer patients located in rural areas the high-quality heart care and treatment currently available only at heart centers in major metropolitan areas. The first phase of the program aims to understand what is required to make remote robotics successful. The development of the program will proceed based on those findings.

With funding from The Leona M. and Harry B. Helmsley Charitable Trust, Corindus and Sanford Health will pursue pioneering remote capabilities for robotic-assisted percutaneous coronary intervention (PCI).

CorPath is an U. S. Food and Drug Administration (FDA)-cleared technology. It enables precise, robotic-assisted angioplasties to open arteries and restore blood flow in patients with coronary artery disease. Physicians sit in a lead-lined interventional cockpit protected from radiation exposure. CorPath allows the cardiologist to advance stents and guidewires millimeter-by-millimeter using joysticks and touchscreen controls. The remote robotics program is intended to extend the capability of CorPath to not just perform angioplasty in the same cath lab, but in labs hundreds of miles away. 

For more information: www.corindus.com


Related Content

News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — People with a small aortic annulus, a part of the heart’s anatomy where the left ventricle meets the ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 8, 2024 — People with diabetes who had suffered a heart attack derived no clinical benefit from edetate disodium ...

Home April 08, 2024
Home
Subscribe Now